【摘要】 目的:探讨鼠神经生长因子治疗2型糖尿病周围神经病变(DPN)临床疗效及安全性。方法:选择89例DPN患者分为观察组45例和对照组44例,两组都给予糖尿病的基础治疗,观察组在基础治疗基础上,加用注射用鼠神经生长因子,对照组加用甲钴胺注射液和丹红注射用,治疗前后测定正中神经和腓总神经的感觉传导速度(SNCV)、运动传导速度(MNCV),行多伦多临床评分系统(TCSS)评分。结果:治疗前,两组患者TCSS评分、正中神经、腓总神经的MNCV及SNCV相似,差异无统计学意义(P>0.05);疗程结束时,两组TCSS评分较治疗前均下降,正中神经、腓总神经的MNCV及SNCV较治疗前均增加,差异有统计学意义(P<0.05),但是观察组改善幅度较对照组更显著(P<0.05)。观察组显效20例、有效23例和无效2例;对照组显效15例、有效21例和无效8例,差异有统计学意义(P<0.05)。两组患者治疗期间未见严重不良反应发生。结论:加用鼠神经生长因子可以有效缓解2型糖尿病DPN的临床症状,提高神经传导速度,安全性高。更多还原

【Abstract】 Objective: To investigate the safety and clinical efficacy of mouse nerve growth factor in treatment of diabetic peripheral neuropathy(DPN) in patients with type 2 diabetes mellitus. Methods: A total of 89 DPN patients were divided into observation group and control group, with 45 patients in the observation group and 44 patients in the control group. Based on the conventional therapy, the patients in observation group were additionally used mouse nerve growth factor for injection, while the patients in control group were additionally used mecobalamin injection and danhong injection(TCM). The pre- and post- therapeutic sensory conduction velocities(SNCV) and motor nerve conduction velocities(MNCV) of the median nerve and common peroneal nerve, and Toronto clinical scoring system(TCSS) scores were determined. Results: Before the treatment, the patients of the two groups had similar TCSS scores, MNCV and SNCV of median nerve and common peroneal nerve, and the differences were statistically insignificant(P>0.05). At the end of treatment, the TCSS score was decreased in two groups and MNCV and SNCV of median nerve and common peroneal nerve was increased, and the differences were statistically significant(P<0.05), but the observation group had greater improvement extent than that of the control group(P<0.05). For the observation group, the curative effect was excellent in 20 patients, effective in 23 patients,and invalid in 2 patients; while for the control group, the curative effect was excellent in 15 patients, effective in 21 patients, and invalid in 8 patients, and the differences were statistically significant(P<0.05). In the treatment period, no severe adverse reactions occurred in the patients of either group. Conclusions: Additional use of mouse nerve growth factor can effectively relieve the clinical symptoms of DPN and elevate the nerve conductive velocity in patients with type 2 diabetes mellitus with high safety.更多还原